Tempus will provide sequencing and analysis for glioblastoma patients in a clinical trial at Duke using engineered poliovirus as a treatment.
The multi-center precision medicine trial has matched approximately 700 patients to 24 treatment arms so far, but some arms appear to be falling short of their recruitment goal.
The combination test will allow clinicians to analyze breast cancer patients for germline hereditary cancer markers at the same time as they search their blood for driver mutations.
In a conference call to discuss the firm's fourth-quarter and full-year earnings, senior management highlighted recent developments and outlined expectations for 2017.
The team found that DNA damage affects a variety of samples and may lead to erroneous low-frequency variant calls unless stringent filtering is applied or the damage is repaired prior to sequencing.
The Cancer Genome Atlas Research Network team uncovered new mutations and amplifications in their cohort of primary cervical cancers.
Biopharma revenue grew from $14.1 million to $19 million in the quarter while clinical testing revenue declined from $12 million to $9.8 million.
Both organizations plan to contribute their respective areas of expertise to work on two research projects to improve patient treatment options and outcomes.
Under the PIPseq program, Columbia University researchers sequenced the exome, transcriptome, or a gene panel in tumors of 101 high-risk pediatric cancer patients.
A small study has found that two next-generation sequencing tests that examined the same cancers uncovered different genetic alterations.
Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.
People around the globe took to the streets to support science — some with signs.
Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.
In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.